Francesco S Mennini1,2, Chiara Bini3, Andrea Marcellusi1,2, Michele Del Vecchio4. 1. Economic Evaluation and HTA (CEIS-EEHTA), Faculty of Economics, University of Rome "Tor Vergata", Via Columbia 2, 00133, Rome, Italy. 2. Institute for Leadership and Management in Health, Kingston University London, Kingston Hill, Kingston upon Thames, London, KT2 7LB, UK. 3. Economic Evaluation and HTA (CEIS-EEHTA), Faculty of Economics, University of Rome "Tor Vergata", Via Columbia 2, 00133, Rome, Italy. chiara.stat@gmail.com. 4. Unit of Medical Oncology 2, Department of Medical Oncology, IRCCS Foundation-National Cancer Institute, Milan, Italy.
Abstract
BACKGROUND AND OBJECTIVE: Immuno-oncology therapies represent a new treatment opportunity for patients affected by metastatic melanoma. The purpose of this study was to estimate the costs of immune-related adverse events (irAEs) associated with the new anti-PD1 immuno-oncology therapies, with the anti-CTLA-4 immuno-oncology therapy and with the combined therapy (CTLA4 + anti-PD1) in patients affected by metastatic melanoma. MATERIALS AND METHODS: A probabilistic cost-of-illness (COI) model was developed to estimate the management costs of grade ≥ 3 adverse events associated with the new anti-PD1 therapies (pembrolizumab and nivolumab), the anti-CTLA-4 therapy (ipilimumab) and the combined therapy CTLA4 + anti-PD1 (nivolumab + ipilimumab) for the treatment of patients with metastatic melanoma from the National Health Service (NHS) perspective in Italy. Identification of the epidemiological and cost parameters was carried out through a systematic literature review (SLR). Univariate and probabilistic sensitivity analyses were performed to account for uncertainty and variation in the model results. RESULTS: The model estimated a cost associated with the management of grade ≥ 3 immune-related adverse events in patients with metastatic melanoma equal to €176.2 (95% CI 63.5-335.0) for anti-CTLA-4 therapy, €48.6 (95% CI 40.1-58.5) for the new anti-PDI therapies and €276.8 (95% CI 240.4-316.2) for the combined therapy. Among the innovative therapies for the considered metastatic melanoma, the combined therapy was the most expensive innovative treatment in terms of event management of immune-related grade ≥ 3 adverse events. CONCLUSION: This study may represent a useful tool to understand the economic burden associated with the management of irAEs associated with patients affected by metastatic melanoma.
BACKGROUND AND OBJECTIVE: Immuno-oncology therapies represent a new treatment opportunity for patients affected by metastatic melanoma. The purpose of this study was to estimate the costs of immune-related adverse events (irAEs) associated with the new anti-PD1 immuno-oncology therapies, with the anti-CTLA-4 immuno-oncology therapy and with the combined therapy (CTLA4 + anti-PD1) in patients affected by metastatic melanoma. MATERIALS AND METHODS: A probabilistic cost-of-illness (COI) model was developed to estimate the management costs of grade ≥ 3 adverse events associated with the new anti-PD1 therapies (pembrolizumab and nivolumab), the anti-CTLA-4 therapy (ipilimumab) and the combined therapy CTLA4 + anti-PD1 (nivolumab + ipilimumab) for the treatment of patients with metastatic melanoma from the National Health Service (NHS) perspective in Italy. Identification of the epidemiological and cost parameters was carried out through a systematic literature review (SLR). Univariate and probabilistic sensitivity analyses were performed to account for uncertainty and variation in the model results. RESULTS: The model estimated a cost associated with the management of grade ≥ 3 immune-related adverse events in patients with metastatic melanoma equal to €176.2 (95% CI 63.5-335.0) for anti-CTLA-4 therapy, €48.6 (95% CI 40.1-58.5) for the new anti-PDI therapies and €276.8 (95% CI 240.4-316.2) for the combined therapy. Among the innovative therapies for the considered metastatic melanoma, the combined therapy was the most expensive innovative treatment in terms of event management of immune-related grade ≥ 3 adverse events. CONCLUSION: This study may represent a useful tool to understand the economic burden associated with the management of irAEs associated with patients affected by metastatic melanoma.
Authors: Eugene D Kwon; Charles G Drake; Howard I Scher; Karim Fizazi; Alberto Bossi; Alfons J M van den Eertwegh; Michael Krainer; Nadine Houede; Ricardo Santos; Hakim Mahammedi; Siobhan Ng; Michele Maio; Fabio A Franke; Santhanam Sundar; Neeraj Agarwal; Andries M Bergman; Tudor E Ciuleanu; Ernesto Korbenfeld; Lisa Sengeløv; Steinbjorn Hansen; Christopher Logothetis; Tomasz M Beer; M Brent McHenry; Paul Gagnier; David Liu; Winald R Gerritsen Journal: Lancet Oncol Date: 2014-05-13 Impact factor: 41.316
Authors: Michele Del Vecchio; Lorenza Di Guardo; Paolo A Ascierto; Antonio M Grimaldi; Vanna Chiarion Sileni; Jacopo Pigozzo; Virginia Ferraresi; Carmen Nuzzo; Gaetana Rinaldi; Alessandro Testori; Pier F Ferrucci; Paolo Marchetti; Federica De Galitiis; Paola Queirolo; Elena Tornari; Riccardo Marconcini; Luana Calabrò; Michele Maio Journal: Eur J Cancer Date: 2013-10-04 Impact factor: 9.162
Authors: Saif S Ahmad; Wendi Qian; Sarah Ellis; Elaine Mason; Muhammad A Khattak; Avinash Gupta; Heather Shaw; Amy Quinton; Jarmila Kovarikova; Kiruthikah Thillai; Ankit Rao; Ruth Board; Jenny Nobes; Angus Dalgleish; Simon Grumett; Anthony Maraveyas; Sarah Danson; Toby Talbot; Mark Harries; Maria Marples; Ruth Plummer; Satish Kumar; Paul Nathan; Mark R Middleton; James Larkin; Paul Lorigan; Matthew Wheater; Christian H Ottensmeier; Pippa G Corrie Journal: Melanoma Res Date: 2015-10 Impact factor: 3.599
Authors: Vanna Chiarion Sileni; Jacopo Pigozzo; Paolo Antonio Ascierto; Antonio Maria Grimaldi; Michele Maio; Lorenza Di Guardo; Paolo Marchetti; Francesco de Rosa; Carmen Nuzzo; Alessandro Testori; Emilia Cocorocchio; Maria Grazia Bernengo; Michele Guida; Riccardo Marconcini; Barbara Merelli; Giorgio Parmiani; Gaetana Rinaldi; Massimo Aglietta; Marco Grosso; Paola Queirolo Journal: J Exp Clin Cancer Res Date: 2014-04-04
Authors: Minkyu Jung; Jeeyun Lee; Tae Min Kim; Dae Ho Lee; Jin Hyung Kang; Sung Young Oh; Soo Jung Lee; Sang Joon Shin Journal: Cancer Res Treat Date: 2016-04-27 Impact factor: 4.679
Authors: Manuel David Gil-Sierra; Maria Del Pilar Briceño-Casado; Marina Sánchez-Hidalgo Journal: Support Care Cancer Date: 2022-01-13 Impact factor: 3.359
Authors: Hayley Standage; Alyssa R Hersh; Aaron Caughey; Matthew Taylor; John Vetto; Dale Han Journal: Ann Surg Oncol Date: 2020-09-19 Impact factor: 5.344
Authors: Massimo Ralli; Andrea Botticelli; Irene Claudia Visconti; Diletta Angeletti; Marco Fiore; Paolo Marchetti; Alessandro Lambiase; Marco de Vincentiis; Antonio Greco Journal: J Immunol Res Date: 2020-06-28 Impact factor: 4.818